Pantoprazole is a drug from the group of proton pump inhibitors. Pantoprazole reduces the overproduction of stomach acid and is therefore used to treat reflux oesophagitis and stomach and duodenal ulcers. It is administered in the form of tablets and is no longer available by prescription.
| Drug | Substance(s) | Authorisation holder |
|---|---|---|
| SOMAC Control 20 mg gastro-resistant tablets | Pantoprazole | Nycomed GmbH |
| PANTOLOC Control 20 mg gastro-resistant tablets | Pantoprazole | Nycomed GmbH |
| PANTECTA Control 20 mg gastro-resistant tablets | Pantoprazole | Nycomed GmbH |
| PANTOZOL Control 20 mg gastro-resistant tablets | Pantoprazole | Nycomed GmbH |
| CONTROLOC Control 20 mg gastro-resistant tablets | Pantoprazole | Nycomed GmbH |
Pantoprazole is an irreversible inhibitor at proton pumps in the gastric mucosa. It irreversibly binds to these pumps and prevents protons, which are essential for the formation of gastric acid, from entering the stomach.
PharmacokineticsPanotprazole is absorbed in the intestine and reaches its highest plasma concentration at 2-3 hours after ingestion. Oral bioavailability is approximately 77% and plasma protein binding is approximately 98%. The active substance is degraded by the CYP-450 system in the liver and the majority is subsequently excreted in the urine.
Pantoprazole is considered to be a very safe drug with few side effects. Rare side effects include dizziness, headache, and diarrhea.
| ATC Code | A02BC02 |
| Formula | C16H15F2N3O4S |
| Molar Mass (g·mol−1) | 383,37 |
| Physical State | solid |
| Melting Point (°C) | 139–140 |
| PKS Value | 3.92 |
| CAS Number | 102625-70-7 |
| PUB Number | 4679 |
| Drugbank ID | DB00213 |
Ad
